3rd Quarter - Report

ROCK & ASSOCIATES for WELLNESS PHARMACY

Firm
Client
Income
$11,250
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 1625 (115th)

Pharmacy PHA

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2871 (115th)

Health Issues HCR

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

LobbyistCovered position, as disclosed
JAMES W ROCK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 2871 (115th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.